ACTRN12606000370505已完成2 期
Phase II study of intravenous Vinorelbine (Navelbine) and Capecitabine (Xeloda) in patients with advanced breast cancer, assessing efficacy and toxicity
Dr. Alison Davis, Dr Stephen Ackland0 个研究点目标入组 50 人开始时间: 2003年12月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- Female
入选标准
- •Advanced/ metastatic breast cancer; maximum of 1 prior chemotherapy for metastatic cancer; at lteat `1 measurable lesion by RECIST; > 18 years; KPS > 80%; adequate organ function
排除标准
- •Life expectance <12 weeks; significant comorbidities; peripheral neuropathy > grade1; other invasive cancers; unable to swallow pills whole
研究者
相似试验
进行中（未招募）
1 期
Phase II trial of oral vinorelbine in a population of patients with lung cancer with an EGFR mutation, after failure to treatment with TKI in first line.EUCTR2012-003361-18-ATPIERRE FABRE MEDICAMENT30
进行中（未招募）
不适用
Phase II trial of oral vinorelbine in a population of patients with lung cancer with an EGFR mutation, after failure to treatment with TKI in first line.Patients with:-Histologically or cytologically confirmed NSCLC (stage IIIB or IV) and-epidermal growth factor receptor (EGFR) positive mutation and-previously treated with tyrosine kinase inhibitor (gefitinib or erlotinib)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003361-18-PLPIERRE FABRE MEDICAMENT75
进行中（未招募）
1 期
Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes)EUCTR2004-000665-35-ESPierre Fabre Medicament
进行中（未招募）
不适用
Phase II study of metronomic oral Vinorelbine plus Bevacizumab as first line treatment for metastatic breast cancer patients - NDMetastatic breast cancerEUCTR2010-022183-12-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
2 期
Meinetenance chemotherapy in lung cancerMalignant neoplasm of lung and brochous.Malignant neoplasm of bronchus and lung including: main bronchus, upper lobe bronchus , Middle lobe bronchus, Lower lobe, bronchus or Bronchus or lung, unspecified.code:C34IRCT2015060822610N1Investigator100